MANNKIND CORP
CUSIP: 56400PAQ5
MANNKIND CORP (MNKD 2.5 03/01/26) — institutional ownership and SEC 13F holdings data. Source: SEC EDGAR 13F filings.
About
MannKind Corporation is a biopharmaceutical company that develops and commercializes inhaled therapeutic products using its proprietary Technosphere pulmonary delivery platform. Its primary marketed product is Afrezza, a rapid-acting inhaled insulin for diabetes, and the company pursues additional pulmonary drug candidates and licensing or collaboration opportunities to leverage its inhalation technology. MannKind operates as a small, commercial-stage specialty biotech focused on formulation and delivery expertise in the pulmonary space.
Institutional Holders
Source: SEC EDGAR 13F-HR filings from institutional investment managers.
Try asking...